Ibalizumab Drug Interactions: What to Avoid and What to Tell Your Doctor

Does Ibalizumab Have Drug Interactions?

The short answer: no known clinically significant drug-drug interactions have been identified with ibalizumab (Trogarzo). This is one of the drug's notable advantages, particularly for the patients it is designed to treat—those with multidrug-resistant HIV (MDR HIV) who are often taking complex combinations of antiretrovirals and other medications.

However, 'no known interactions' does not mean 'no need to disclose medications.' Here's what you need to know.

Why Ibalizumab Has No Drug Interactions

Most drug interactions occur when two drugs compete for the same liver enzymes (like CYP3A4) or transport proteins. Ibalizumab bypasses all of those pathways:

It is not metabolized in the liver. As a large protein (monoclonal antibody), ibalizumab is broken down through normal protein catabolism—the same process that breaks down natural antibodies.

It is not eliminated by the kidneys. Unlike many small molecule drugs, ibalizumab is not renally cleared, so there are no interactions related to renal transporters.

Its mechanism is entirely outside the cell. Ibalizumab works by binding to the CD4 receptor on the surface of T cells—a mechanism entirely distinct from all other antiretroviral drugs, which work inside the cell.

Based on this pharmacokinetic profile, no formal drug interaction studies have been conducted with ibalizumab, and none are expected to be clinically significant.

What You Still Need to Tell Your Doctor

Even with no known interactions, you must always give your healthcare provider a complete, up-to-date medication list before each infusion. Reasons include:

New interactions may be identified over time as post-marketing data accumulates. The ibalizumab patient population is relatively small, and rare interactions may not yet have been reported.

Interactions among the other antiretrovirals in your optimized background regimen (OBR) are still clinically relevant—for example, fostemsavir has CYP3A4 interactions, and some antiretrovirals interact with common co-medications.

Your overall health picture matters for infusion safety monitoring, including knowing about supplements, herbal products, and OTC medications.

Ibalizumab and Alcohol

While ibalizumab itself is not metabolized by liver enzymes that alcohol affects, alcohol may increase the risk of dizziness—one of ibalizumab's reported side effects (occurring in approximately 8% of patients). Avoid alcohol on infusion days and discuss any regular alcohol use with your provider.

Ibalizumab and Vaccines

There are no specific contraindications to vaccines with ibalizumab. However, the safety of live or live-attenuated vaccines in infants who were exposed to ibalizumab in utero (while their mother was being treated) is unknown due to the drug's potential to cause transient immunosuppression in the newborn. If you are the parent or guardian of an infant exposed to ibalizumab in utero, discuss the vaccination schedule with your pediatrician.

How Ibalizumab Compares to Other MDR HIV Drugs for Drug Interactions

In the landscape of drugs used for MDR HIV-1, ibalizumab stands out for its clean interaction profile:

Fostemsavir (Rukobia): Significant interactions with strong CYP3A4 inducers (rifampin, carbamazepine, phenytoin, St. John's Wort)—which can dramatically reduce fostemsavir blood levels. Contraindicated with strong inducers.

Lenacapavir (Sunlenca): Has notable interactions with strong and moderate CYP3A4 inducers and certain other drugs. Requires careful review of the full medication list.

Ibalizumab: No known drug-drug interactions with antiretrovirals or other medications. No dose adjustments needed for any co-administered drugs.

For a comprehensive overview of ibalizumab's side effects, see: Ibalizumab Side Effects: What to Expect and When to Call Your Doctor.

Need help locating an ibalizumab infusion site? medfinder calls providers near you so you don't have to.